Arbutus Biopharma Corp OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Arbutus Biopharma Corp (ABUS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$49.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-12
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was -$49.00K.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was -$97.00K.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was $58.00K, a 73.39% decline year-over-year.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-06-30 was -$21.00K, a 133.33% decline year-over-year.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was $37.00K, a 87.06% decline from fiscal 2024.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was $286.00K, a 86.16% decline from fiscal 2023.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $2.07M.
- Arbutus Biopharma Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$2.15M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.00K 10-Q · filed 2026-08-12 | -$146.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$97.00K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $37.00K 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-13 | $37.00K derived: sum of 2 quarters · filed 2026-08-12 | $6.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$21.00K 10-Q · filed 2026-08-12 | -$52.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$31.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $286.00K 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $218.00K 10-Q · filed 2025-11-13 | $281.00K derived: sum of 2 quarters · filed 2025-11-13 | $331.00K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $63.00K 10-Q · filed 2025-11-13 | $113.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $50.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $2.07M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $584.00K 10-Q · filed 2024-11-06 | $750.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.60M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $166.00K 10-Q · filed 2024-11-06 | $1.02M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $854.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$2.15M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$907.00K 10-Q · filed 2023-11-07 | -$1.60M derived: sum of 2 quarters · filed 2023-11-07 | -$2.67M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$691.00K 10-Q · filed 2023-11-07 | -$1.76M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | -$1.07M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |